| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 25 | 2024 | 220 | 4.010 |
Why?
|
| Stomach Neoplasms | 12 | 2022 | 269 | 3.130 |
Why?
|
| General Surgery | 8 | 2022 | 235 | 2.240 |
Why?
|
| Pancreaticoduodenectomy | 15 | 2020 | 82 | 1.970 |
Why?
|
| Pancreatic Neoplasms | 19 | 2020 | 659 | 1.970 |
Why?
|
| Soft Tissue Neoplasms | 11 | 2024 | 129 | 1.600 |
Why?
|
| Internship and Residency | 9 | 2022 | 1037 | 1.440 |
Why?
|
| Retroperitoneal Neoplasms | 8 | 2021 | 44 | 1.400 |
Why?
|
| Surgical Procedures, Operative | 8 | 2024 | 205 | 1.290 |
Why?
|
| Laparoscopy | 8 | 2022 | 766 | 1.250 |
Why?
|
| Neoadjuvant Therapy | 10 | 2021 | 361 | 1.250 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2024 | 1352 | 1.230 |
Why?
|
| Adenocarcinoma | 12 | 2021 | 1184 | 1.190 |
Why?
|
| Extremities | 11 | 2022 | 167 | 1.160 |
Why?
|
| Pancreatectomy | 6 | 2020 | 156 | 1.090 |
Why?
|
| Postoperative Complications | 14 | 2024 | 2285 | 1.030 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 318 | 1.010 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 303 | 1.010 |
Why?
|
| Carcinoma, Pancreatic Ductal | 8 | 2020 | 112 | 0.950 |
Why?
|
| Gastrectomy | 6 | 2022 | 68 | 0.900 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2012 | 23 | 0.840 |
Why?
|
| Education, Medical, Graduate | 5 | 2020 | 388 | 0.830 |
Why?
|
| Neurilemmoma | 1 | 2021 | 34 | 0.750 |
Why?
|
| Pancreatitis | 3 | 2012 | 86 | 0.750 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 44 | 0.710 |
Why?
|
| Humans | 93 | 2024 | 88611 | 0.700 |
Why?
|
| Retrospective Studies | 41 | 2024 | 8893 | 0.690 |
Why?
|
| Middle Aged | 56 | 2024 | 25699 | 0.690 |
Why?
|
| Pancreas | 2 | 2011 | 242 | 0.670 |
Why?
|
| Male | 65 | 2024 | 42012 | 0.650 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 182 | 0.650 |
Why?
|
| Critical Care | 3 | 2020 | 378 | 0.610 |
Why?
|
| Precancerous Conditions | 2 | 2009 | 200 | 0.600 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 41 | 0.570 |
Why?
|
| Aged | 43 | 2024 | 18932 | 0.570 |
Why?
|
| Body Composition | 1 | 2017 | 70 | 0.560 |
Why?
|
| Lymph Node Excision | 2 | 2010 | 221 | 0.560 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2019 | 479 | 0.540 |
Why?
|
| Hepatectomy | 5 | 2023 | 172 | 0.530 |
Why?
|
| Survival Rate | 17 | 2024 | 1883 | 0.530 |
Why?
|
| Prognosis | 16 | 2024 | 3750 | 0.530 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2019 | 2638 | 0.520 |
Why?
|
| Neuroendocrine Tumors | 4 | 2023 | 109 | 0.500 |
Why?
|
| Female | 59 | 2024 | 45759 | 0.500 |
Why?
|
| United States | 28 | 2024 | 6882 | 0.490 |
Why?
|
| Nomograms | 4 | 2022 | 29 | 0.480 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2009 | 72 | 0.460 |
Why?
|
| Referral and Consultation | 1 | 2016 | 342 | 0.460 |
Why?
|
| Preoperative Care | 4 | 2021 | 398 | 0.450 |
Why?
|
| Peritoneal Lavage | 1 | 2013 | 11 | 0.450 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2020 | 295 | 0.450 |
Why?
|
| Cholangiocarcinoma | 3 | 2009 | 76 | 0.440 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 6723 | 0.440 |
Why?
|
| Torso | 4 | 2020 | 12 | 0.430 |
Why?
|
| Bile Duct Neoplasms | 3 | 2009 | 89 | 0.430 |
Why?
|
| Pancreatic Fistula | 3 | 2020 | 16 | 0.410 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2009 | 8 | 0.400 |
Why?
|
| Margins of Excision | 6 | 2021 | 39 | 0.400 |
Why?
|
| Follow-Up Studies | 14 | 2024 | 3655 | 0.400 |
Why?
|
| Liver Neoplasms | 4 | 2023 | 771 | 0.400 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 1983 | 0.400 |
Why?
|
| Ampulla of Vater | 2 | 2014 | 23 | 0.380 |
Why?
|
| Adult | 29 | 2024 | 26348 | 0.380 |
Why?
|
| Informed Consent | 3 | 2024 | 273 | 0.380 |
Why?
|
| Robotic Surgical Procedures | 3 | 2022 | 298 | 0.360 |
Why?
|
| Pancreatic Cyst | 1 | 2010 | 28 | 0.360 |
Why?
|
| Prospective Studies | 8 | 2020 | 4271 | 0.350 |
Why?
|
| Mucor | 1 | 2009 | 3 | 0.350 |
Why?
|
| Piperazines | 2 | 2012 | 280 | 0.350 |
Why?
|
| Amphotericin B | 1 | 2009 | 34 | 0.350 |
Why?
|
| Personnel Selection | 2 | 2020 | 60 | 0.350 |
Why?
|
| Mucormycosis | 1 | 2009 | 15 | 0.350 |
Why?
|
| Length of Stay | 6 | 2020 | 726 | 0.340 |
Why?
|
| Digestive System Neoplasms | 1 | 2009 | 21 | 0.340 |
Why?
|
| Triazoles | 1 | 2009 | 100 | 0.330 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2406 | 0.330 |
Why?
|
| Pyrimidines | 2 | 2012 | 372 | 0.330 |
Why?
|
| Specialties, Surgical | 3 | 2020 | 65 | 0.330 |
Why?
|
| Antifungal Agents | 1 | 2009 | 119 | 0.330 |
Why?
|
| Professional Autonomy | 2 | 2020 | 41 | 0.320 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 329 | 0.310 |
Why?
|
| Guideline Adherence | 1 | 2010 | 226 | 0.310 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 149 | 0.310 |
Why?
|
| Treatment Outcome | 15 | 2023 | 8178 | 0.300 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2593 | 0.300 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 431 | 0.290 |
Why?
|
| Xanthomatosis | 1 | 2007 | 5 | 0.290 |
Why?
|
| Betacoronavirus | 5 | 2020 | 260 | 0.290 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2007 | 9 | 0.290 |
Why?
|
| Predictive Value of Tests | 6 | 2020 | 1709 | 0.290 |
Why?
|
| Patient Selection | 2 | 2021 | 689 | 0.290 |
Why?
|
| Sarcopenia | 2 | 2018 | 13 | 0.280 |
Why?
|
| Orbital Diseases | 1 | 2007 | 21 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 837 | 0.280 |
Why?
|
| Clinical Competence | 6 | 2022 | 780 | 0.270 |
Why?
|
| Disease-Free Survival | 8 | 2021 | 1213 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2019 | 2286 | 0.250 |
Why?
|
| Faculty, Medical | 2 | 2020 | 184 | 0.250 |
Why?
|
| Survival Analysis | 8 | 2020 | 1542 | 0.250 |
Why?
|
| Sulfites | 1 | 2024 | 30 | 0.240 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 119 | 0.240 |
Why?
|
| Pandemics | 5 | 2020 | 760 | 0.240 |
Why?
|
| Propensity Score | 6 | 2020 | 146 | 0.230 |
Why?
|
| Kupffer Cells | 2 | 2001 | 13 | 0.230 |
Why?
|
| Organizational Innovation | 2 | 2020 | 41 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 612 | 0.220 |
Why?
|
| Limb Salvage | 2 | 2020 | 33 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2018 | 406 | 0.220 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2022 | 4 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 1039 | 0.210 |
Why?
|
| Chondrosarcoma | 1 | 2022 | 48 | 0.210 |
Why?
|
| Biliary Tract Diseases | 1 | 2022 | 36 | 0.210 |
Why?
|
| Databases, Factual | 7 | 2020 | 846 | 0.200 |
Why?
|
| Liposarcoma | 1 | 2021 | 12 | 0.200 |
Why?
|
| Metastasectomy | 1 | 2021 | 9 | 0.200 |
Why?
|
| Chicago | 3 | 2020 | 1411 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 275 | 0.190 |
Why?
|
| Arm | 1 | 2021 | 97 | 0.190 |
Why?
|
| Leg | 1 | 2021 | 140 | 0.190 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 7 | 0.190 |
Why?
|
| Catheter Ablation | 1 | 2023 | 251 | 0.190 |
Why?
|
| Risk Factors | 9 | 2022 | 5449 | 0.190 |
Why?
|
| Educational Measurement | 3 | 2013 | 230 | 0.190 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 642 | 0.190 |
Why?
|
| Macrophage Activation | 1 | 2001 | 49 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 863 | 0.190 |
Why?
|
| Cholestasis | 1 | 2001 | 47 | 0.190 |
Why?
|
| Human Experimentation | 1 | 2001 | 39 | 0.180 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2000 | 4 | 0.180 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 367 | 0.180 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2000 | 3 | 0.180 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2000 | 4 | 0.180 |
Why?
|
| Liver Regeneration | 1 | 2000 | 37 | 0.180 |
Why?
|
| Education, Distance | 1 | 2020 | 25 | 0.180 |
Why?
|
| Computer-Assisted Instruction | 1 | 2020 | 44 | 0.180 |
Why?
|
| Leukocyte Count | 1 | 2020 | 222 | 0.180 |
Why?
|
| Imatinib Mesylate | 2 | 2012 | 127 | 0.180 |
Why?
|
| Surgical Oncology | 1 | 2020 | 27 | 0.180 |
Why?
|
| Leiomyosarcoma | 1 | 2020 | 43 | 0.180 |
Why?
|
| Parathyroid Glands | 1 | 1999 | 75 | 0.170 |
Why?
|
| Prenatal Diagnosis | 1 | 2000 | 110 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 396 | 0.170 |
Why?
|
| DNA Methylation | 1 | 2024 | 656 | 0.170 |
Why?
|
| Workload | 1 | 2020 | 129 | 0.170 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1296 | 0.170 |
Why?
|
| Parathyroidectomy | 1 | 1999 | 78 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 93 | 0.170 |
Why?
|
| Program Evaluation | 2 | 2020 | 303 | 0.170 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 1999 | 68 | 0.170 |
Why?
|
| Benzamides | 2 | 2012 | 239 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 120 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2020 | 187 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 333 | 0.160 |
Why?
|
| Neutrophils | 1 | 2020 | 308 | 0.160 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2024 | 473 | 0.160 |
Why?
|
| Cystadenoma, Serous | 2 | 2010 | 15 | 0.160 |
Why?
|
| Asthma | 1 | 2007 | 973 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 185 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2022 | 376 | 0.160 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 29 | 0.160 |
Why?
|
| Triage | 1 | 2019 | 111 | 0.160 |
Why?
|
| Abdominal Neoplasms | 1 | 2018 | 39 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2020 | 470 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.160 |
Why?
|
| Conversion to Open Surgery | 1 | 2018 | 11 | 0.160 |
Why?
|
| Organoids | 1 | 2018 | 62 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2018 | 64 | 0.150 |
Why?
|
| Thoracic Neoplasms | 1 | 2018 | 64 | 0.150 |
Why?
|
| Thorax | 1 | 2018 | 77 | 0.150 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 34 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2336 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 319 | 0.150 |
Why?
|
| Macrophages | 1 | 2001 | 572 | 0.150 |
Why?
|
| Treatment Failure | 2 | 2012 | 289 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 179 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 1999 | 319 | 0.140 |
Why?
|
| Pediatrics | 1 | 2001 | 351 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 149 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2020 | 2837 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2019 | 269 | 0.130 |
Why?
|
| Psoas Muscles | 1 | 2015 | 2 | 0.130 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1520 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2020 | 251 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 165 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2019 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 960 | 0.120 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2014 | 3 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 634 | 0.120 |
Why?
|
| Decision Making | 1 | 2020 | 661 | 0.120 |
Why?
|
| Liver | 2 | 2017 | 1244 | 0.120 |
Why?
|
| Fatigue | 1 | 2015 | 178 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 858 | 0.120 |
Why?
|
| Recurrence | 2 | 2012 | 1168 | 0.120 |
Why?
|
| Teaching | 2 | 2013 | 147 | 0.120 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2014 | 7 | 0.120 |
Why?
|
| Duodenal Neoplasms | 1 | 2014 | 19 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 335 | 0.120 |
Why?
|
| Age Factors | 4 | 2020 | 1863 | 0.110 |
Why?
|
| Neoplasms | 2 | 2024 | 3009 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 407 | 0.110 |
Why?
|
| Awards and Prizes | 1 | 2013 | 37 | 0.110 |
Why?
|
| Registries | 4 | 2018 | 759 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 995 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 304 | 0.110 |
Why?
|
| Gastric Mucosa | 1 | 2012 | 66 | 0.110 |
Why?
|
| Safety | 1 | 2013 | 151 | 0.100 |
Why?
|
| Cholangitis | 1 | 2012 | 19 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2014 | 80 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2536 | 0.100 |
Why?
|
| Duodenal Diseases | 1 | 2012 | 23 | 0.100 |
Why?
|
| Choledocholithiasis | 1 | 2012 | 13 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2024 | 866 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 865 | 0.100 |
Why?
|
| Genomics | 1 | 2017 | 747 | 0.100 |
Why?
|
| Leadership | 1 | 2013 | 136 | 0.100 |
Why?
|
| Diverticulum | 1 | 2012 | 45 | 0.100 |
Why?
|
| Histocytochemistry | 1 | 2011 | 130 | 0.100 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 68 | 0.100 |
Why?
|
| Microscopy | 1 | 2011 | 88 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 774 | 0.090 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cystadenoma, Papillary | 1 | 2010 | 9 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1709 | 0.090 |
Why?
|
| Bilirubin | 2 | 2001 | 130 | 0.090 |
Why?
|
| Gadolinium | 2 | 2001 | 103 | 0.090 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2010 | 48 | 0.090 |
Why?
|
| ROC Curve | 3 | 2019 | 773 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 76 | 0.090 |
Why?
|
| Incidence | 3 | 2022 | 1592 | 0.090 |
Why?
|
| Phenotype | 3 | 2007 | 2435 | 0.090 |
Why?
|
| Bile Duct Diseases | 1 | 2009 | 22 | 0.090 |
Why?
|
| Endoscopy | 1 | 2012 | 344 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2010 | 281 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 499 | 0.080 |
Why?
|
| Feedback | 1 | 2009 | 134 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 222 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2010 | 124 | 0.080 |
Why?
|
| Barrett Esophagus | 1 | 2009 | 93 | 0.080 |
Why?
|
| Students, Medical | 1 | 2013 | 418 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2001 | 1237 | 0.070 |
Why?
|
| Patient Readmission | 3 | 2016 | 349 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 799 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 383 | 0.070 |
Why?
|
| Histiocytes | 1 | 2007 | 22 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2020 | 559 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1588 | 0.070 |
Why?
|
| Sclerosis | 1 | 2007 | 29 | 0.070 |
Why?
|
| Palliative Care | 2 | 2020 | 264 | 0.070 |
Why?
|
| Orbit | 1 | 2007 | 38 | 0.070 |
Why?
|
| Adenoma, Islet Cell | 1 | 2006 | 28 | 0.070 |
Why?
|
| Plasma Cells | 1 | 2007 | 82 | 0.070 |
Why?
|
| Gallbladder Neoplasms | 1 | 2006 | 23 | 0.070 |
Why?
|
| Time Factors | 2 | 2017 | 5319 | 0.070 |
Why?
|
| Age of Onset | 1 | 2007 | 311 | 0.070 |
Why?
|
| Frozen Sections | 1 | 2005 | 49 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 6218 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 597 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 248 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2001 | 2445 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2024 | 40 | 0.060 |
Why?
|
| Frail Elderly | 2 | 2015 | 81 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1205 | 0.060 |
Why?
|
| Rats | 2 | 2001 | 4041 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2001 | 306 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2018 | 548 | 0.060 |
Why?
|
| Microwaves | 1 | 2023 | 36 | 0.060 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 47 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2024 | 269 | 0.060 |
Why?
|
| Adenoma | 1 | 2005 | 243 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2001 | 2346 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 399 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 177 | 0.060 |
Why?
|
| Illinois | 2 | 2014 | 465 | 0.050 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 82 | 0.050 |
Why?
|
| Duodenum | 2 | 2014 | 102 | 0.050 |
Why?
|
| Bile | 1 | 2022 | 57 | 0.050 |
Why?
|
| Learning Curve | 1 | 2022 | 18 | 0.050 |
Why?
|
| Helsinki Declaration | 1 | 2001 | 4 | 0.050 |
Why?
|
| Body Fluids | 1 | 2001 | 35 | 0.050 |
Why?
|
| Ki-67 Antigen | 2 | 2014 | 66 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 418 | 0.050 |
Why?
|
| Cancer Pain | 1 | 2020 | 3 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2000 | 59 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2322 | 0.040 |
Why?
|
| Immunoradiometric Assay | 1 | 1999 | 2 | 0.040 |
Why?
|
| Documentation | 1 | 2001 | 103 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 73 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 360 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 98 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2000 | 152 | 0.040 |
Why?
|
| Forearm | 1 | 1999 | 31 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 149 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2000 | 68 | 0.040 |
Why?
|
| Trachea | 1 | 2001 | 291 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2746 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2001 | 594 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2020 | 87 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 88 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2000 | 153 | 0.040 |
Why?
|
| Vital Signs | 1 | 2019 | 38 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 691 | 0.040 |
Why?
|
| Fibrosis | 1 | 2000 | 237 | 0.040 |
Why?
|
| Body Weight | 1 | 2000 | 455 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 1999 | 216 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2018 | 38 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2018 | 25 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 1999 | 342 | 0.040 |
Why?
|
| Collagen | 1 | 2000 | 296 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2000 | 253 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 283 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 622 | 0.040 |
Why?
|
| Medical Staff, Hospital | 2 | 2009 | 108 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 294 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 342 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 69 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2000 | 250 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 686 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 35 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 57 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2000 | 205 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2020 | 335 | 0.040 |
Why?
|
| Health Services Research | 1 | 2018 | 137 | 0.040 |
Why?
|
| Wound Healing | 1 | 2020 | 356 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 96 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 46 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 565 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2019 | 235 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 328 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 138 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1868 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 27233 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2014 | 902 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 115 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2017 | 164 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2017 | 104 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 191 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2000 | 948 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 450 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2020 | 770 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 230 | 0.030 |
Why?
|
| Skin | 1 | 1999 | 581 | 0.030 |
Why?
|
| Pregnancy | 2 | 2001 | 2996 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2000 | 686 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 902 | 0.030 |
Why?
|
| Graft Survival | 1 | 1999 | 916 | 0.030 |
Why?
|
| Disease Progression | 1 | 2000 | 1490 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 340 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 365 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 605 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1867 | 0.030 |
Why?
|
| Contrast Media | 1 | 2000 | 1088 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 9157 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 333 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 961 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 369 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2016 | 167 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 1402 | 0.030 |
Why?
|
| Duodenoscopy | 1 | 2014 | 8 | 0.030 |
Why?
|
| Lung | 1 | 2001 | 1243 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 306 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 294 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2001 | 3678 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 871 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1759 | 0.030 |
Why?
|
| Competency-Based Education | 1 | 2013 | 36 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1999 | 853 | 0.030 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2012 | 26 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 159 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 158 | 0.030 |
Why?
|
| Jejunum | 1 | 2012 | 80 | 0.030 |
Why?
|
| Career Choice | 1 | 2013 | 145 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1843 | 0.020 |
Why?
|
| Education, Medical | 1 | 2013 | 243 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1063 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 40 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2009 | 86 | 0.020 |
Why?
|
| Child | 1 | 2001 | 7089 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1096 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 804 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1694 | 0.020 |
Why?
|
| Internet | 1 | 2009 | 318 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 67 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2009 | 384 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2006 | 84 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 80 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 196 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 11710 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 409 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2006 | 729 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 575 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1790 | 0.010 |
Why?
|
| Ligation | 1 | 2001 | 51 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 259 | 0.010 |
Why?
|
| Sheep | 1 | 2001 | 250 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 1256 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 307 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 508 | 0.010 |
Why?
|
| Pressure | 1 | 2001 | 166 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 696 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 575 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2001 | 1234 | 0.010 |
Why?
|